Does Blue Cross Blue Shield of Illinois Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Decisions Are Complicated

Tirzepatide is a once-weekly subcutaneous injection that acts on two separate hormone receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That dual-agonist mechanism distinguishes it from semaglutide (Ozempic, Wegovy), which targets only the GLP-1 receptor. The FDA approved tirzepatide as Mounjaro in May 2022 for adults with type 2 diabetes mellitus and as Zepbound in November 2023 specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea. 1

Coverage decisions are complicated primarily because the two FDA-approved brand names carry different indication codes, and insurers including BCBSIL adjudicate them separately. A patient whose plan covers Mounjaro for type 2 diabetes may find that the same plan excludes Zepbound for obesity, or vice versa. The BCBSIL Medical Policy framework, which applies across its commercial PPO, HMO, and Illinois marketplace exchange plans, lists obesity pharmacotherapy under a distinct policy category from diabetes pharmacotherapy. 2

The legal backdrop matters here. The Affordable Care Act does not mandate coverage of obesity drugs for commercial plans. That omission means BCBSIL has contractual latitude to exclude weight-loss medications entirely on certain benefit designs, even when the FDA has approved the drug for that purpose. 3

How BCBSIL Structures Tirzepatide Coverage Across Plan Types

BCBSIL administers plans for individuals, small groups, large employer groups, and the Illinois Health Insurance Marketplace. Coverage rules differ meaningfully across each category.

Employer-sponsored fully insured plans. BCBSIL sets the formulary. Most standard formularies place tirzepatide on Tier 3 or Tier 4, requiring prior authorization. Some large self-insured employers carve out obesity medications entirely; others add Zepbound as a voluntary benefit rider. Your Summary of Benefits and Coverage (SBC) document, required under 29 CFR 2590.715-2715, will state whether "weight loss drugs" are a covered benefit category. 4

Self-insured employer plans (ASO plans). BCBSIL acts only as a third-party administrator. The employer dictates the formulary. BCBSIL's standard medical policies apply as a default, but the employer can override them. This means two employees with BCBSIL ID cards may have completely different tirzepatide coverage based on who their employer is.

Illinois marketplace exchange plans. These plans follow Affordable Care Act essential health benefit rules. Obesity drug coverage is not an essential health benefit, so marketplace plans vary. The 2024 and 2025 BCBSIL Blue Choice Preferred PPO marketplace plans have not uniformly included Zepbound or Mounjaro as covered drugs in the standard benefit tier structure. Patients should verify using BCBSIL's online drug lookup tool at bcbsil.com with their specific plan ID before assuming coverage exists.

Medicaid managed care (BCBSIL / Meridian). Illinois Medicaid historically excluded most weight-loss drugs but began covering select GLP-1 agents for Medicaid members with type 2 diabetes. Coverage of Zepbound for obesity under Illinois Medicaid managed care plans remains limited as of mid-2025. The Illinois Department of Healthcare and Family Services publishes its preferred drug list at hfs.illinois.gov, and that list should be checked directly. 5

Medicare Part D. Federal law prohibits Medicare Part D from covering drugs used for weight loss, even FDA-approved ones such as Zepbound, unless the drug is prescribed for a non-obesity indication. Mounjaro for type 2 diabetes may be covered under Part D if the plan includes it on formulary. 6

The Clinical Evidence Supporting Tirzepatide That Insurers Review

When a BCBSIL medical director evaluates a prior authorization request, the clinical dossier behind tirzepatide is substantial. Knowing this evidence helps clinicians write stronger prior auth letters.

In SURMOUNT-1 (N=2,539), adults without diabetes randomized to tirzepatide 15 mg achieved a mean body weight reduction of 22.5% over 72 weeks, compared with 2.4% in the placebo group (P<0.001). 7 That magnitude of weight loss exceeds the 15% benchmark that many BCBSIL obesity drug policies cite as clinically meaningful threshold language in their medical policy documents.

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg, and produced 12.4 lb more weight loss at 40 weeks (P<0.001 for both). 8 This head-to-head comparison with semaglutide matters when a prior auth is being reviewed against a step therapy protocol that requires failing semaglutide first.

SURMOUNT-2 enrolled adults with type 2 diabetes and obesity. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 15.7% versus 3.3% placebo (P<0.001), demonstrating efficacy even in the metabolically compromised population that most commonly presents for BCBSIL prior auth review. 9

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "We recommend adding weight-loss medications as an adjunct to lifestyle interventions in individuals with a BMI of 30 or higher or a BMI of 27 or higher with weight-related comorbidities." 10 That recommendation carries Grade 1 (strong) evidence classification and can be cited verbatim in a prior auth appeal letter.

The American Diabetes Association's 2024 Standards of Care in Diabetes notes that tirzepatide demonstrated "superior glycemic and weight outcomes compared with semaglutide" in head-to-head trials and recommends it as a preferred agent for adults with type 2 diabetes and obesity. 11

BCBSIL Prior Authorization Criteria: What the Policy Actually Requires

BCBSIL's prior authorization requirements for tirzepatide (as of mid-2025 policy cycles) generally follow a consistent framework, though individual plan riders can modify specific thresholds. The following criteria represent the standard medical policy language applied to most commercial BCBSIL plans:

For Mounjaro (tirzepatide for type 2 diabetes):

• Confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x)
• HbA1c of 7.0% or higher documented within the past 6 months
• At least one prior oral antidiabetic agent tried and failed, or a clinical contraindication documented by the prescribing physician
• Prescriber must be an MD, DO, NP, or PA with prescribing authority in Illinois

For Zepbound (tirzepatide for obesity):

• BMI of 30 or higher documented in the chart within 90 days, OR BMI of 27 or higher with at least one qualifying comorbidity (hypertension, T2DM, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of a structured diet and exercise program attempted for at least 3 to 6 months (BCBSIL commonly requests 3 months of behavioral intervention notes)
• No exclusion condition such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Prescriber attestation that obesity is the primary indication, not cosmetic weight loss

Step therapy requirements vary. Some BCBSIL commercial plans require documented failure of at least one other anti-obesity medication such as phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) before approving tirzepatide. Others require only a semaglutide trial. Checking the specific step therapy protocol attached to your plan's formulary is the single most important pre-submission step a prescribing clinician can take. 12

Approval periods are typically 12 months, with renewal requiring documented response (at least 5% body weight reduction or HbA1c improvement for diabetes indications) and ongoing prescriber attestation.

How to Submit a Prior Authorization That Gets Approved

Submission quality strongly predicts outcome. BCBSIL accepts prior auth requests through Availity (the primary portal), by fax using the BCBSIL Prior Authorization Request Form, or via phone at 1-800-972-8088 for physician offices.

A high-quality prior auth package for tirzepatide should include:

1. The patient's most recent weight and BMI measurement with the date
2. HbA1c or fasting glucose result if submitting for the diabetes indication
3. Encounter notes documenting the diet and exercise counseling provided (dates and provider)
4. A narrative letter from the prescribing clinician citing SURMOUNT-1 or SURPASS-2 outcomes and the Endocrine Society guideline recommendation
5. A list of prior medications tried, with dates started, doses used, and reasons for discontinuation

BCBSIL is required under Illinois Department of Insurance regulations to issue a decision on non-urgent prior authorization requests within 2 business days for electronic submissions. Urgent requests require a decision within 24 hours. If BCBSIL requests additional information, the clock pauses until the information is received. 13

What to Do When BCBSIL Denies Coverage

Denial is not the end of the road. BCBSIL denials for tirzepatide most commonly cite one of three reasons: the plan explicitly excludes weight-loss medications, the step therapy requirement was not met, or the prior auth documentation was incomplete.

Internal appeal. Illinois law requires BCBSIL to allow at least one internal appeal. The appeal must be filed within 180 days of the denial notice. BCBSIL must issue a decision within 30 days for non-urgent internal appeals. The appeal letter should cite the Endocrine Society's Grade 1 guideline recommendation and the specific SURMOUNT-1 outcome data showing 22.5% mean weight reduction. 14

External independent review. If the internal appeal is denied, Illinois law (215 ILCS 5/155.36) entitles patients to an external independent review by a state-certified Independent Review Organization (IRO). The IRO decision is binding on BCBSIL for medical necessity determinations. Requests for external review must typically be filed within 4 months of the internal appeal denial.

Step therapy exception. Illinois enacted a step therapy reform law (Public Act 101-452) requiring commercial insurers including BCBSIL to grant step therapy exceptions when the required first-step drug is contraindicated, has previously been tried and failed, or is clinically inappropriate for the patient. A prescribing physician's attestation of clinical inappropriateness is sufficient under the statute to trigger an exception review. 15

Peer-to-peer review. Before filing a formal appeal, requesting a peer-to-peer call with the BCBSIL medical director who issued the denial resolves a meaningful proportion of cases. This call should be requested within 5 to 7 days of receiving the denial notice. The treating clinician speaks directly with the BCBSIL reviewer and can present clinical nuances that did not fit in the structured prior auth form.

Cost Reduction Strategies When Coverage Is Denied or Partial

Eli Lilly's savings programs represent the most immediate cost-reduction option for commercially insured patients who are denied BCBSIL coverage or face high cost-sharing.

The Mounjaro Savings Card reduces out-of-pocket cost to as low as $25 per month for eligible commercially insured patients for up to 12 months. Eligibility requires that the patient have commercial insurance (Medicare and Medicaid are excluded) and a valid prescription. The list price of tirzepatide is approximately $1,069.08 for a 4-week supply regardless of dose. 16

The Zepbound savings card program offers similar pricing tiers for commercially insured patients: as low as $25/month for those with insurance coverage and up to $550/month for those paying entirely out of pocket through Lilly's direct program. Patients who are uninsured or paying out of pocket may access Zepbound vials (a lower-cost formulation compared to the autoinjector pen) through LillyDirect at reduced pricing, with the 2.5 mg and 5 mg vials listed at $349 per month as of early 2025.

Health savings account (HSA) or flexible spending account (FSA) funds may be used to pay for tirzepatide when prescribed for a qualifying medical condition such as type 2 diabetes. When tirzepatide is prescribed solely for weight loss without a qualifying diagnosis, HSA/FSA eligibility may depend on the account plan rules. 17

Patient assistance programs through Lilly Cares Foundation provide tirzepatide at no cost to uninsured or underinsured patients meeting income thresholds (generally at or below 400% of the federal poverty level). Applications are submitted through lillycares.com with prescriber support documentation. 18

Monitoring Requirements After BCBSIL Approves Tirzepatide

Approval is the start of ongoing documentation requirements. BCBSIL renewal authorizations (typically at 12 months) require evidence of clinical response. For the diabetes indication, the standard renewal threshold is an HbA1c reduction of at least 0.5 percentage points. For the obesity indication, BCBSIL commonly requires at least 5% total body weight loss from baseline to renew authorization, consistent with FDA prescribing information guidance for evaluating response at 16 weeks. 19

Clinicians prescribing tirzepatide should schedule a 16-week assessment visit specifically to capture and document the weight response. Missing this visit is a common reason renewal authorizations are denied for lack of supporting documentation.

Adverse events that BCBSIL reviewers watch for during renewal include pancreatitis, gallbladder disease, and severe gastrointestinal symptoms. The SURMOUNT-1 trial reported nausea in 32.7% of patients on the 15 mg dose, vomiting in 18.2%, and diarrhea in 23.0%, with most events rated mild to moderate and occurring primarily during dose escalation. 20 Documenting tolerability at each encounter strengthens the renewal case.

The standard dose escalation schedule begins at tirzepatide 2.5 mg once weekly for 4 weeks, increasing in 2.5 mg increments every 4 weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg depending on tolerability and response. The FDA prescribing information specifies this titration schedule and notes that doses above 15 mg weekly have not been studied. 21

For cardiovascular risk documentation, the SURPASS-CVOT trial (NCT04255433) is ongoing. Interim data and the trial design have been described in the literature, and cardiovascular outcome data will likely influence future BCBSIL coverage policies once published, in the same way that LEADER (liraglutide) and SUSTAIN-6 (semaglutide) data shaped earlier GLP-1 formulary decisions. 22

Comparing Tirzepatide to Semaglutide for BCBSIL Formulary Purposes

BCBSIL formularies that include semaglutide (Ozempic for diabetes, Wegovy for obesity) do not automatically include tirzepatide. The two drug classes are often managed under separate utilization management programs. Knowing where each drug sits on the BCBSIL formulary matters for patients switching between agents.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo. 23 Tirzepatide's 22.5% weight reduction in SURMOUNT-1 represents a difference of approximately 7.6 percentage points. That numerical gap is meaningful when arguing in an appeal that semaglutide is clinically inferior for a specific patient who needs greater weight loss to achieve a therapeutic goal such as qualifying for bariatric surgery or resolving severe sleep apnea.

BCBSIL step therapy protocols on some plans require failing Wegovy before authorizing Zepbound for obesity, on the rationale that semaglutide is available at a lower tier cost. A prescriber can counter this with the SURPASS-2 head-to-head data and a documented clinical rationale for why greater weight reduction is medically necessary for that individual patient. 24

Some BCBSIL commercial plans have begun placing both Wegovy and Zepbound on Tier 4 specialty tiers with prior authorization, requiring patients to pay 20 to 30 percent coinsurance after deductible. For plans with a $2,000 deductible and 25% coinsurance, the annual patient cost for tirzepatide at list price could reach $4,800 or more before any savings card is applied. Running this calculation for your patient before prescribing helps set realistic expectations and triggers the savings card conversation early. 25